Fly News Breaks for April 18, 2018
RARE
Apr 18, 2018 | 07:43 EDT
JMP Securities analyst Liisa Bayko raised her price target on Ultragenyx to $74 from $70 after the company received Crysvita approval in the U.S., as anticipated, and estimated a net annual cost of treatment of about $160K for pediatric patients and about $200K for adults. Management remains comfortable with its U.S. prevalence estimates of 9,000 adult and 3,000 pediatric patients, noted Bayko, who keeps an Outperform rating on the shares.
News For RARE From the Last 2 Days